Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

Bristol-Myers Squibb stock gains on FDA approval of schizophrenia treatment

admin by admin
September 27, 2024
in Stock
0
Bristol-Myers Squibb stock gains on FDA approval of schizophrenia treatment
0
SHARES
10
VIEWS
Share on FacebookShare on Twitter

Investing.com — Bristol-Myers Squibb (NYSE:BMY) shares rallied 4.45% in premarket trading Friday following the announcement that the U.S. Food and Drug Administration (FDA) approved the company’s new schizophrenia treatment, COBENFY.

The drug, which combines xanomeline and trospium chloride, represents a major breakthrough, with the company claiming it is the first new pharmacological approach to treat schizophrenia in decades.

COBENFY is a muscarinic agonist that targets M1 and M4 receptors, offering a new mechanism of action distinct from current therapies.

Chris Boerner, CEO of Bristol-Myers Squibb, described the approval as a “landmark.”

“After more than 30 years, there is now an entirely new pharmacological approach for schizophrenia — one that has the potential to change the treatment paradigm,” he said in a statement.

The approval is based on data from the EMERGENT clinical program, which demonstrated “significant reductions of schizophrenia symptoms compared to placebo.”

The drug is also said to have a favorable safety profile. Analysts see this as a positive development for COBENFY’s market potential.

Barclays analysts said the news validates the company’s acquisition of Karuna and gives “Bristol another key top-line driver over the balance of the decade.”

They added that the drug’s list price of $1,850 per month (~$22,500 annually) suggests potential upside beyond their initial expectations.

Truist analysts emphasized the first-in-class status of COBENFY, noting that it is the first new mechanism of action approved for schizophrenia in over 30 years.

They estimate that the drug could generate $4.2 billion in peak sales, surpassing the consensus estimate of $3.9 billion. The analysts also highlighted Bristol-Myers’ future plans to expand COBENFY’s indications to include Alzheimer’s-related psychosis and bipolar disorder.

Meanwhile, BMO Capital told investors in a note that the news is a “significant positive for BMY shares.”

“Today’s announcement validates Bristol’s $12.7B acquisition of Karuna and allows the company to start changing the narrative around the ongoing triple patent-cliff,” said BMO Capital. “Following today’s approval we estimate $2.4B in peak sales for COBENFY in Schizophrenia and $3.9B in Alz psychosis, pushing our target to $53/share.”

This post appeared first on investing.com

Previous Post

China cuts short-term borrowing costs

Next Post

Ceres surges after ‘solid numbers update’

admin

admin

Next Post
Ceres surges after ‘solid numbers update’

Ceres surges after ‘solid numbers update’

Trending News

ITOps market poised for double-digit growth as AI reshapes industry, Raymond James

ITOps market poised for double-digit growth as AI reshapes industry, Raymond James

December 29, 2024
RBC’s top 10 questions and answers on biotech stocks

RBC’s top 10 questions and answers on biotech stocks

November 16, 2024
US stocks slide at open: Dow Jones slips 100 points, Nasdaq down 0.4%

US stocks slide at open: Dow Jones slips 100 points, Nasdaq down 0.4%

June 17, 2025
Subscribe to Insightful Word


    Recent News

    Dow futures soar 250 points today: 5 things to know before Wall Street opens

    Dow futures soar 250 points today: 5 things to know before Wall Street opens

    August 7, 2025
    Affirm stock price is rising: is it a buy before earnings?

    Affirm stock price is rising: is it a buy before earnings?

    August 7, 2025
    Intel stock plunges sharply after Trump calls on CEO to resign: here’s why rebound may take time

    Intel stock plunges sharply after Trump calls on CEO to resign: here’s why rebound may take time

    August 7, 2025
    Goldman Sachs boosts Nvidia price target to $200 ahead of Q2 earnings

    Goldman Sachs boosts Nvidia price target to $200 ahead of Q2 earnings

    August 7, 2025

    Recent News

    Dow futures soar 250 points today: 5 things to know before Wall Street opens

    Dow futures soar 250 points today: 5 things to know before Wall Street opens

    August 7, 2025
    Affirm stock price is rising: is it a buy before earnings?

    Affirm stock price is rising: is it a buy before earnings?

    August 7, 2025

    Latest News

    • Dow futures soar 250 points today: 5 things to know before Wall Street opens
    • Affirm stock price is rising: is it a buy before earnings?
    • Intel stock plunges sharply after Trump calls on CEO to resign: here’s why rebound may take time

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.